Vertex
Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has
initiated a Phase I clinical study for VX-770, a novel, oral drug candidate
that specifically targets a key mechanism underlying cystic fibrosis (CF).
The study will evaluate the safety, tolerability and pharmacokinetics of
escalating single and multiple doses of VX-770 in healthy volunteers, and
also will evaluate single doses of VX-770 in patients with CF. The study is
expected to enroll more than 50 individuals. In March 2006, Vertex and
Cystic Fibrosis Foundation Therapeutics Inc. (CFFT) entered into a
collaboration to accelerate clinical development of VX-770. CFFT is the
nonprofit drug discovery and development affiliate of the Cystic Fibrosis
Foundation. Vertex retains worldwide rights to develop and commercialize
VX-770.
"This first clinical study for VX-770 signifies an important milestone
in the productive collaborative history that we have shared with Vertex in
the discovery of novel CF therapies," said Robert J. Beall, Ph.D.,
President and Chief Executive Officer of the Cystic Fibrosis Foundation and
CFFT. "We believe that compounds such as VX-770 have great potential to
change the course of CF, and we are pleased to support the accelerated
development of VX-770 in early clinical studies."
"VX-770 is the first drug candidate to have emerged from our innovative
CF research efforts, and the initiation of this Phase I study represents an
exciting new stage in the development of this compound," said John Alam,
M.D., Executive Vice President, Medicines Development, and Chief Medical
Officer of Vertex. "Laboratory results for VX-770 have been highly
encouraging and support the initiation of this first clinical study. We
look forward to evaluating VX-770 in both healthy volunteers and patients
with CF in the coming months to determine the next steps for the VX-770
development program."
Study Design
The Phase I study for VX-770 announced today is expected to enroll more
than 50 individuals, including healthy volunteers and patients with CF.
Dosing has been initiated in the first cohort of healthy volunteers, and is
expected to progress to patients with CF later this year. Healthy
volunteers in the Phase I study will receive escalating doses of VX-770 for
treatment durations of up to 14 days, and patients with CF will receive
single doses of VX-770.
Fast Track Designation for VX-770
Vertex also today announced that the U.S. Food and Drug Administration
(FDA) has granted Fast Track designation to VX-770. The FDA granted Fast
Track designation to VX-770 for the following reasons:
Cystic fibrosis (CF) is a serious and life-threatening illness in which
mucus plugging, infection, and inflammation in the lungs lead to a
decline in pulmonary function and significant morbidity and mortality.
VX-770 is intended to preserve pulmonary function, decrease morbidity,
and prolong survival in patients with CF by decreasing cycles of mucus
plugging, infection, and inflammation in the lungs.
Under the FDA Modernization Act of 1997, Fast Track designation
indicates that the FDA will facilitate the development and may expedite the
review of a drug if it is intended for the treatment of a serious or
life-threatening condition and demonstrates the potential to address an
unmet medical need for such a condition.
About VX-770
VX-770 was advanced into preclinical development based on a successful
research collaboration with CFFT that incorporated capabilities and
proprietary research from Vertex's San Diego research site. VX-770 may act
to restore the function of the cystic fibrosis transmembrane conductance
regulator (CFTR) protein, the defective cell membrane protein responsible
for the progression of CF. Defects in the CFTR protein affect the transport
of chloride and other ions across cells, and lead to the accumulation of
thick, sticky mucus in the lungs of patients with CF. This mucus fosters
chronic infection and inflammation, and results in irreversible lung
damage. Potentiator compounds such as VX-770 are designed to increase the
probability that the CFTR channel is open, which could result in an
increase in chloride transport across the cell surface in some patients. In
laboratory experiments, using cells from patients with CF where CFTR
proteins are present on the cell surface, VX-770 has restored the gating
activity of defective CFTR channels.
Collaborative History with CFFT
Vertex initiated its CF research program in May 2000 in collaboration
with CFFT, which offers special expertise and experience in CF drug
discovery and development. Vertex and CFFT expanded the agreement in May
2004, and in March 2006, entered into a new collaboration for the
accelerated development of VX- 770. Under the collaboration, CFFT will
provide to Vertex approximately $13.3 million to support clinical
development of VX-770 through the fourth quarter of 2007. In addition to
the development collaboration for VX-770, in January 2006, Vertex and CFFT
entered into an expanded research collaboration to discover novel compounds
known as correctors, which may work by increasing the number of CFTR
channels on the cell surface. To date, CFFT has provided to Vertex more
than $40 million for CF research.
About Cystic Fibrosis and the Cystic Fibrosis Foundation
Cystic fibrosis is a genetic disease affecting approximately 30,000
people in the United States. A defect in the CFTR gene causes the body to
produce abnormally thick, sticky mucus that leads to chronic,
life-threatening lung infections and impairs digestion. When the CF
Foundation was established in 1955, few children lived to attend elementary
school. Today, because of research and care supported by the CF Foundation
with money raised through donations from families, corporations and
foundations -- the median predicted age of survival for people with CF is
now more than 36 years.
The Cystic Fibrosis Foundation, headquartered in Bethesda, MD, is a
donor-supported, nonprofit organization committed to finding therapies and
ultimately a cure for CF, and to improving the lives of those with the
disease. For more information on CF and the programs of the CF Foundation,
call (800) FIGHT CF or visit cff.
Vertex Safe Harbor Statement
This press release may contain forward-looking statements, including
statements that Vertex expects (i) that the Phase I clinical study for
VX-770 is expected to enroll more than 50 individuals; (ii) that the study
will evaluate the safety, tolerability and pharmacokinetics of escalating
single and multiple doses of VX-770 in healthy volunteers and single doses
of VX-770 in patients with CF; (iii) that compounds such as VX-770 have the
potential to change the course of CF; (iv) that it will evaluate VX-770 in
the coming months to determine the next steps for the VX-770 development
program; (v) to begin dosing VX-770 in patients with CF later this year;
and (vi) VX-770 may act to restore the function of the cystic fibrosis
transmembrane conductance regulator (CFTR) protein. While management makes
its best efforts to be accurate in making forward-looking statements, such
statements are subject to risks and uncertainties that could cause Vertex's
actual results to vary materially. These risks and uncertainties include,
among other things, the possibility that CFFT could terminate its financial
support under its agreements with Vertex early, risks that efforts to
develop VX-770 may not proceed due to financial, technical, scientific,
commercial or other reasons, that clinical trials may not proceed as
planned due to technical, scientific, supply or patient enrollment issues,
that actual clinical studies of VX-770 will not reflect the results
obtained in pre-clinical and nonclinical testing, and other risks listed
under Risk Factors in Vertex's Form 10-K filed with the Securities and
Exchange Commission on March 16, 2006.
Lexiva is a registered trademark of the GlaxoSmithKline group of
companies.
Vertex's press releases are available at vrtx.
Vertex Pharmaceuticals Incorporated
vrtx
View drug information on Lexiva.
Комментариев нет:
Отправить комментарий